Widely used:Recently Viewed
Clear All$439.37
$14.38
(3.38%)
As on 12-May-2025 16:24EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$109,136 Mln
P/E Ratio
--
P/B Ratio
6.77
Industry P/E
--
Debt to Equity
0
ROE
-0.06 %
ROCE
-2.93 %
Div. Yield
0 %
Book Value
--
EPS
-3.92
CFO
$16,606.24 Mln
EBITDA
$15,617.12 Mln
Net Profit
$14,123.87 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| 9.11 | -9.26 | -3.48 | 3.92 | 23.20 | 9.02 | 13.48 |
|
BSE Sensex
| 5.34 | 9.68 | 8.04 | 13.44 | 15.08 | 21.17 | 11.60 |
|
S&P 100
| -2.55 | 8.86 | -4.32 | 14.27 | 16.46 | 16.01 | 11.84 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Vertex Pharmaceuticals (VRTX)
| -1.02 | 40.90 | 31.50 | -7.08 | 7.94 | 32.13 | 10.52 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 270.19 | 33,685.74 | -- | -364.98 | |
| 156.13 | 25,775.27 | 20.33 | 20.61 | |
| 575.63 | 59,129.31 | 13.42 | 15.33 | |
| 25.26 | 17,794.28 | -- | -- |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age... and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Read more
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Executive Chairman
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Vertex Pharmaceuticals Incorporated (VRTX) stood at $ 26,664 Mln as on 31-Mar-25
The share price of Vertex Pharmaceuticals Incorporated (VRTX) is $439.37 (NASDAQ) as of 12-May-2025 16:24 EDT. Vertex Pharmaceuticals Incorporated (VRTX) has given a return of 23.2% in the last 3 years.
Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $ 109,136 Mln as on 09-May-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Vertex Pharmaceuticals Incorporated (VRTX) is 6.77 times as on 09-May-2025, a 218% premium to its peers’ median range of 2.13 times.
Since, TTM earnings of Vertex Pharmaceuticals Incorporated (VRTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Vertex Pharmaceuticals Incorporated (VRTX) and enter the required number of quantities and click on buy to purchase the shares of Vertex Pharmaceuticals Incorporated (VRTX).
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
The CEO & director of Dr. Jeffrey Marc Leiden M.D., Ph.D.. is Vertex Pharmaceuticals Incorporated (VRTX), and CFO & Sr. VP is Dr. Jeffrey Marc Leiden M.D., Ph.D..
There is no promoter pledging in Vertex Pharmaceuticals Incorporated (VRTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
6,538
|
|
|
3,357
|
|
|
2,706
|
|
|
1,742
|
| Vertex Pharmaceuticals Incorporated (VRTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-5.14
|
|
Operating margin(%)
|
-2.56
|
|
Net Margin(%)
|
-8.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Vertex Pharmaceuticals Incorporated (VRTX) was $0 Mln.
